Andrew Dean

8.1k citations
104 papers · 1.7k · 3 hit papers · h-index 17

Impact in

  • Oncology top 2%
    • Pancreatic and Hepatic Oncology Research
    • Vascular Tumors and Angiosarcomas
    • PARP inhibition in cancer therapy
    • CAR-T cell therapy research
    • Ovarian cancer diagnosis and treatment

Papers in

    • Pancreatic and Hepatic Oncology Research 44
    • Colorectal Cancer Treatments and Studies 16
    • Cancer Treatment and Pharmacology 13
    • PARP inhibition in cancer therapy 13
    • Lung Cancer Research Studies 10
    • Cancer Genomics and Diagnostics 25

Andrew Dean

97 papers receiving 1.7k citations

Andrew Dean's Hit Papers

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial 2023 · 215 citations
2150+3+7Years since publication100200300400500

Peers

Andrew Dean
Comparison fields: 5 of 80
  • Oncology 942
  • Reproductive Medicine 206
  • Pulmonary and Respiratory Medicine 576
  • Cancer Research 197
  • Obstetrics and Gynecology 72
Replace Claudia Lebedinsky with:
Claudia Lebedinsky United States
D. Fennelly Ireland
Tatsunori Shimoi Japan
Shingo Noura Japan
Annamaria H. Zimmermann United States
Philippe Follana France
Alessandra Ravaioli Italy
Pavlos Papakostas Greece
Giovanni Fucà Italy
Andrew Dean relative to Claudia Lebedinsky United States Claudia Lebedinsky's profile →
Citations per field
00.5×10×15.6×
Claudia Lebedinsky · 1×
Citations per year

Countries citing papers authored by Andrew Dean

Since Specialization
Citations

This map shows the geographic impact of Andrew Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Dean more than expected).

Fields of papers citing papers by Andrew Dean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Dean. The network helps show where Andrew Dean may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Dean, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Dean Line = papers co-authored together Andrew Dean links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 104 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Hit paper breakdown →
2015585
2
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Hit paper breakdown →
2023242
3
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2023215
4 202255
5 202349
6 201441
7 201738
8 202134
9 201823
10 201722
11 201821
12 201918
13 201518
14 199118
15 199718
16 202217
17 202017
18 202216
19 201015
20 201514

About Andrew Dean

Andrew Dean is a scholar working on Oncology, Cancer Research, Reproductive Medicine, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 104 papers that have together received 1.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (44 papers), Cancer Genomics and Diagnostics (25 papers), Ovarian cancer diagnosis and treatment (18 papers), Colorectal Cancer Treatments and Studies (16 papers), Cancer Treatment and Pharmacology (13 papers), PARP inhibition in cancer therapy (13 papers), Lung Cancer Research Studies (10 papers) and Neuroendocrine Tumor Research Advances (6 papers). The work is most often cited by research in Oncology (942 citations), Reproductive Medicine (206 citations), Pulmonary and Respiratory Medicine (576 citations), Cancer Research (197 citations) and Obstetrics and Gynecology (72 citations). Andrew Dean has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Roland E. Knoblauch, Shreyaskumar Patel, Robin L. Jones, Alexander I. Spira, Robert G. Maki, Martee L. Hensley, Mohammed Milhem, Margaret von Mehren, George D. Demetri and Kristen N. Ganjoo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Gynecological Cancer, Clinical Colorectal Cancer and Gynecologic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact